ALPS Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

ALPS Advisors’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-93,705	Closed	-$2.22M	–	874
2019 Q3	$2.22M	Buy	93,705 +5,160	+6%	+$153K	0.02%	204
2019 Q2	$2.66M	Buy	+88,545	New	+$2.03M	0.02%	200
2018 Q4	–	Sell	-57,230	Closed	-$1.03M	–	986
2018 Q3	$1.03M	Buy	57,230 +10,377	+22%	+$123K	0.01%	387
2018 Q2	$466K	Buy	46,853 +5,241	+13%	+$36.2K	﹤0.01%	656
2018 Q1	$221K	Buy	41,612 +16,539	+66%	+$118K	﹤0.01%	832
2017 Q4	$213K	Buy	25,073 +2,806	+13%	+$34.5K	﹤0.01%	806
2017 Q3	$325K	Buy	22,267 +1,897	+9%	+$28.7K	﹤0.01%	722
2017 Q2	$382K	Buy	+20,370	New	+$460K	﹤0.01%	690

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ALPS Advisors's RARX Position: Q4 2019 in Review

ALPS Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 93,705 shares — an estimated $2.22M sold.

ALPS Advisors first reported a position in RARX in Q2 2017 and held it in 8 quarters. The position peaked at $2.66M in Q2 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

ALPS Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
ALPS Advisors sold 93,705 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $2.22M.
ALPS Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 8 quarters.
ALPS Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $2.66M in Q2 2019.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on ALPS Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.